Article
Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.
ESMO open - 1 Aug 2022
Ramarao-Milne P, Kondrashova O, Patch A-M, Nones K, Koufariotis L T, Newell F, Addala V, Lakis V, Holmes O, Leonard C, Wood S, Xu Q, Mukhopadhyay P, Naeini M M, Steinfort D, Williamson J P, Bint M, Pahoff C, Nguyen P T, Twaddell S, Arnold D, Grainge C, Basirzadeh F, Fielding D, Dalley A J, Chittoory H, Simpson P T, Aoude L G, Bonazzi V F, Patel K, Barbour A P, Fennell D A, Robinson B W, Creaney J, Hollway G, Pearson J V, Waddell N
Abstract excerpt
BACKGROUND: Next-generation sequencing is used in cancer research to identify somatic and germline mutations, which can predict sensitivity or resistance to therapies, and may be a useful tool to reveal drug repurposing opportunities between tumour types. Multigene panels are used in clinical practice for detecting targetable mutations. However, the value of clinical whole-exome sequencing (WES) and whole-genome...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.